Patrick Soon-Shiong
About Patrick Soon-Shiong
Medical doctor Patrick Soon-Shiong invented the cancer drug Abraxane. It became a blockbuster thanks to its efficacy against pancreatic cancer.
He sold his drug companies Abraxis in 2010 and American Pharmaceutical Partners in 2008 for a combined $9.1 billion.
He took his cancer drug maker NantKwest public in 2015 and his biotech startup NantHealth public in 2016.
He owns NantWorks, a network of health startups, and has stakes in media firm Tribune Publishing and the Los Angeles Lakers.
He bought the Los Angeles Times and San Diego Tribune for $500 million in June 2018.
In May 2020, Soon-Shiong's ImmunityBio was selected for the federal government's "Operation Warp Speed" to help quickly develop a Covid-19 vaccine.
Personal stats
Citizenship
United States of AmericaSource of wealth
PharmaceuticalsResidence
Los Angeles, CaliforniaMarital status
MarriedBirth date
07/29/52 (age 72)Number of children
2Education
Master of Science, University of British Columbia; Bachelor of Arts/Science, University of Witwatersrand; Medical Doctor, University of WitwatersrandSelf-made
self-madePatrick Soon-Shiong’s fortune is worth
troy ounces of gold
median U.S. household
median U.S. income
U.S. credit card volume
GDP of the United States
United States debt
Net worth history
Annual ranking
Did you know?
Soon-Shiong graduated from high school at age 16 and became a doctor at 23.
Net worth over time
Real-time ranking
Financial assets
US OTC | MDRX-US
AllscriptsNASDAQ | BNTC-US
Benitec BiopharmaNYSE | BMY-US
Bristol-Myers Squibb Co.NASDAQ | CELG-US
Celgene CorporationNASDAQ | CELGZ-US
Contingent Value Rights for Celgene CorporationLONDON | DCTA-GB
Directa Plusundefined | undefined
HeliogenNASDAQ | IBRX-US
ImmunityBio IncNASDAQ | IBRX-US
ImmunityBio IncNASDAQ | JAKK-US
JAKKS Pacific Inc.TORONTO | LMNL-CA
Liminal BioSciencesUS OTC | NHIQ-US
NantHealthNASDAQ | RDNT-US
RadNet Inc.US OTC | SRNE-US
Sorrento TherapeuticsNASDAQ | TPCO-US
Tribune PublishingImages © Forbes.com. All rights reserved.